A multi-arm, open label, clinical study that will be conducted at one hospital to understand the safety and benefits of Aller GI health supplements in controlling sinusitis, rhinitis and skin allergy
Phase 3
Completed
- Conditions
- Health Condition 1: J019- Acute sinusitis, unspecifiedHealth Condition 2: L239- Allergic contact dermatitis, unspecified causeHealth Condition 3: J300- Vasomotor rhinitis
- Registration Number
- CTRI/2024/02/063075
- Lead Sponsor
- IFE AVEDA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1.Patients of age between 18 to 65 years.
2.Patients having symptoms of allergic rhinitis, sinusitis and skin allergy.
3.Scores from the global scale atopic dermatitis vIGA
4.Patients willing to comply by the study procedures and sign an informed consent form.
Exclusion Criteria
1.Patients with poorly controlled Hypertension or with uncontrolled Diabetes Mellitus and having a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method